Sponsor: ECOG-ACRIN Cancer Research Group
Sponsor Study ID: EA8211
Study Title: Phase III Randomized Trial of Stereotactic ablative radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma
CTO #: 104031
NCT Number: NCT05863351
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Kidney
Study Objectives: To compare overall survival (OS) between patients receiving SAbR + systemic therapy (SABR+ST) versus systemic therapy (ST) only. To compare average AE score between SAbR+ST arm and ST only arm.